Published in J Med Chem on November 27, 2008
Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms. J Chem Inf Model (2012) 1.29
Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol (2012) 1.24
Activation of CAR and PXR by Dietary, Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary Metabolism, and Cell Proliferation. Curr Pharmacogenomics Person Med (2009) 1.10
Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos (2010) 0.92
Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact (2010) 0.90
Differential effects of clinically used derivatives and metabolites of artemisinin in the activation of constitutive androstane receptor isoforms. Br J Pharmacol (2012) 0.86
Identification of novel activators of constitutive androstane receptor from FDA-approved drugs by integrated computational and biological approaches. Pharm Res (2012) 0.86
Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective. Drug Metab Rev (2012) 0.81
Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol (2008) 2.02
Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol (2012) 1.82
Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol (2005) 1.74
Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther (2009) 1.66
Structural mechanism of the recovery stroke in the myosin molecular motor. Proc Natl Acad Sci U S A (2005) 1.66
The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. ChemMedChem (2009) 1.64
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One (2009) 1.55
Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J Med Chem (2008) 1.31
Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem (2007) 1.19
Activation, regulation, and inhibition of DYRK1A. FEBS J (2010) 1.18
An update on the constitutive androstane receptor (CAR). Drug Metabol Drug Interact (2013) 1.16
Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem (2007) 1.16
Cancer treatment of the future: inhibitors of histone methyltransferases. Int J Biochem Cell Biol (2008) 1.14
Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Curr Pharm Des (2008) 1.11
A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett (2007) 1.09
The potential of anti-malarial compounds derived from African medicinal plants, part I: a pharmacological evaluation of alkaloids and terpenoids. Malar J (2013) 1.07
Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem (2008) 1.06
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem (2006) 1.06
Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem (2006) 1.06
CamMedNP: building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med (2013) 1.05
Degradation of tropoelastin by matrix metalloproteinases--cleavage site specificities and release of matrikines. FEBS J (2010) 1.02
NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets. Med Res Rev (2010) 1.02
A structure-activity relationship study of catechol-O-methyltransferase inhibitors combining molecular docking and 3D QSAR methods. J Comput Aided Mol Des (2003) 1.02
N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. J Med Chem (2003) 1.01
An in silico approach to discovering novel inhibitors of human sirtuin type 2. J Med Chem (2004) 0.99
Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing. ChemMedChem (2008) 0.99
Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch Pharm (Weinheim) (2011) 0.98
Modulation of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. Mol Pharmacol (2002) 0.98
Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog (2013) 0.97
Extracellular and intracellular barriers in non-viral gene delivery. J Control Release (2003) 0.97
Histone deacetylase inhibitors that target tubulin. Cancer Lett (2009) 0.97
Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity. Eur J Pharm Sci (2004) 0.96
Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. J Med Chem (2012) 0.96
Molecular dynamics simulations of bovine rhodopsin: influence of protonation states and different membrane-mimicking environments. J Mol Model (2005) 0.96
Alginate-based microencapsulation of retinal pigment epithelial cell line for cell therapy. Biomaterials (2007) 0.95
Cell-surface glycosaminoglycans inhibit cation-mediated gene transfer. J Gene Med (2004) 0.95
Oxadiazole-carbonylaminothioureas as SIRT1 and SIRT2 inhibitors. J Med Chem (2008) 0.95
Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs). Bioorg Med Chem (2007) 0.95
Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J Med Chem (2005) 0.94
Development of a 3D model for the human cannabinoid CB1 receptor. J Med Chem (2004) 0.93
Effluxing ABC transporters in human corneal epithelium. J Pharm Sci (2010) 0.93
Comparative and pharmacophore model for deacetylase SIRT1. J Comput Aided Mol Des (2006) 0.93
Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg Med Chem (2011) 0.93
Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des (2007) 0.92
BRUTUS: optimization of a grid-based similarity function for rigid-body molecular superposition. 1. Alignment and virtual screening applications. J Med Chem (2005) 0.92
The potential of anti-malarial compounds derived from African medicinal plants, part II: a pharmacological evaluation of non-alkaloids and non-terpenoids. Malar J (2014) 0.91
Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors. ChemMedChem (2009) 0.91
Ligand recognition by drug-activated nuclear receptors PXR and CAR: structural, site-directed mutagenesis and molecular modeling studies. Mini Rev Med Chem (2006) 0.91
Regulation of the human tyrosinase gene in retinal pigment epithelium cells: the significance of transcription factor orthodenticle homeobox 2 and its polymorphic binding site. Mol Vis (2012) 0.90
Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharmacol (2002) 0.90
Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem (2005) 0.90
Homology modeling and molecular dynamics simulations of Dengue virus NS2B/NS3 protease: insight into molecular interaction. J Mol Recognit (2010) 0.90
AfroDb: a select highly potent and diverse natural product library from African medicinal plants. PLoS One (2013) 0.90
Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. J Med Chem (2013) 0.90
Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. Biomaterials (2012) 0.90
Pyridylalanine-containing hydroxamic acids as selective HDAC6 inhibitors. ChemMedChem (2009) 0.90
The role of histone demethylases in cancer therapy. Mol Oncol (2012) 0.90
Amino acids important for ligand specificity of the human constitutive androstane receptor. J Biol Chem (2004) 0.89
Cameroonian medicinal plants: a bioactivity versus ethnobotanical survey and chemotaxonomic classification. BMC Complement Altern Med (2013) 0.89
Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. Chem Biol (2013) 0.89
Polyplex-mediated gene transfer and cell cycle: effect of carrier on cellular uptake and intracellular kinetics, and significance of glycosaminoglycans. J Gene Med (2007) 0.88
N(epsilon)-thioacetyl-lysine-containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors. J Med Chem (2009) 0.88
Inhibitors to understand molecular mechanisms of NAD(+)-dependent deacetylases (sirtuins). Biochim Biophys Acta (2010) 0.88
Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2. J Med Chem (2011) 0.87
Freeze-drying of cationic polymer DNA complexes enables their long-term storage and reverse transfection of post-mitotic cells. J Control Release (2005) 0.87
Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J Med Chem (2005) 0.86
Characterization of the binding properties of SIRT2 inhibitors with a N-(3-phenylpropenoyl)-glycine tryptamide backbone. Bioorg Med Chem (2008) 0.86
Carbamate prodrug concept for hydroxamate HDAC inhibitors. ChemMedChem (2011) 0.86
Dual action of oestrogens on the mouse constitutive androstane receptor. Biochem J (2003) 0.86
Screen of pseudopeptidic inhibitors of human sirtuins 1-3: two lead compounds with antiproliferative effects in cancer cells. J Med Chem (2013) 0.85
Novel 3-arylideneindolin-2-ones as inhibitors of NAD+ -dependent histone deacetylases (sirtuins). J Med Chem (2010) 0.85
Mind the methyl: methyllysine binding proteins in epigenetic regulation. ChemMedChem (2014) 0.85
Integrative and personalized QSAR analysis in cancer by kernelized Bayesian matrix factorization. J Chem Inf Model (2014) 0.85
Critical comparison of virtual screening methods against the MUV data set. J Chem Inf Model (2009) 0.85
Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorg Med Chem (2011) 0.85
The role of cell cycle on polyplex-mediated gene transfer into a retinal pigment epithelial cell line. J Gene Med (2005) 0.85
Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists. J Med Chem (2006) 0.85
N,N'-Bisbenzylidenebenzene-1,4-diamines and N,N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors. J Med Chem (2006) 0.84
Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. BMC Bioinformatics (2012) 0.84
Molecular modeling of potential anticancer agents from African medicinal plants. J Chem Inf Model (2014) 0.84
Evolutionary history and functional characterization of the amphibian xenosensor CAR. Mol Endocrinol (2011) 0.84
New in vitro tools to study human constitutive androstane receptor (CAR) biology: discovery and comparison of human CAR inverse agonists. Mol Pharm (2011) 0.83
Insights into the degradation of human elastin by matrilysin-1. Biochimie (2010) 0.83
BRUTUS: optimization of a grid-based similarity function for rigid-body molecular superposition. II. Description and characterization. J Comput Aided Mol Des (2006) 0.83